Avantor Investor Day Presentation Deck

3. BIOPRODUCTION Recent market evolutions play to Avantor's strengths Biologics (mAbs) of Avantor's ~65% Bioproduction revenue¹ Viral Vector / Cell & Gene therapy Bioengineered (mRNA) Navantor™ - Pace of FDA approvals MARKET TRENDS - New therapeutic - New modalities areas (Alzheimer's) 1. FY21 estimates, excluding pending M&A HIGH PURITY CHEMICALS AVANTOR RELEVANCE DIRECT HYDRATED DISPENSE SOLUTIONS MATERIALS GMP REAGENTS AT SCALE 29

View entire presentation